Back to your original subject, I believe it depends on the data from the phase III in 1st line study where HLA-A*0201+ was not an inclusion criteria, and whether this study will be required for approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.